Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of glioma patient-derived xenografts treated by DMSO or LY2109761

ABSTRACT: RNA-seq of glioma patient-derived xenografts treated by DMSO or LY2109761

PROVIDER: PRJNA437856 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6825131.fastq.gz	Fastqsanger.gz
	SRR6825132.fastq.gz	Fastqsanger.gz
	SRR6825133.fastq.gz	Fastqsanger.gz
	SRR6825134.fastq.gz	Fastqsanger.gz
	SRR6825135.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

RNA-seq of glioma patient-derived xenografts treated by DMSO or LY2109761

Project description:We employed the patient-derived xenografts (PDX) model to test the efficiency of LY2109761 in vivo. The drug was intraperitoneally administered, and the mice were sacrificed on the 31st day. The tumors were excised and subjected to RNA-seq. All groups had similar expression density distributions. Hierarchical clustering showed that the same processing groups had the closest distances.

2021-03-07 | GSE111673 | GEO

Patch-seq of human patient-derived diffuse midline glioma xenografts

Project description:Patch-seq of human patient-derived diffuse midline glioma xenografts

| PRJNA921869 | ENA

Thoracic patient-derived xenografts

Project description:Thoracic patient-derived xenografts

| PRJNA339191 | ENA

Patch-seq of human patient-derived diffuse midline glioma xenografts

Project description:Treatment-resistance of lethal high-grade brain tumors including H3K27M diffuse midline gliomas is thought to arise in part from transcriptional and electrophysiological heterogeneity. These phenotypes are readily studied in isolation using single-cell RNA-seq and whole-cell patch clamping, respectively, but their simultaneous capture is now possible by aspirating a cell's contents into a patch pipet after electrophysiology recordings using a method called 'patch-seq'. Here, we adapt this method to characterize the gene expression programs and functional responses of patient-derived glioma xenografts to neuronal firing at single-cell resolution.

2023-03-01 | GSE222398 | GEO

miRNA-seq of glioma patient tissues treated by DMSO or LY2109761

Project description:miRNA-seq of glioma patient tissues treated by DMSO or LY2109761

| PRJNA437874 | ENA

RNA-seq of glioma patient tissues treated by DMSO or LY2109761

Project description:RNA-seq of glioma patient tissues treated by DMSO or LY2109761

| PRJNA437873 | ENA

miRNA-seq of glioma patient tissues treated by DMSO or LY2109761

Project description:Glioma tissues from patients were cultured in complete DMEM and treated with either DMSO or LY2109761, an inhibitor of TGFBR2. Tissue blocks of TBD0207 and TBD0220 were subjected to miRNA-seq.

2021-03-07 | GSE111675 | GEO

RNA-seq of glioma patient tissues treated by DMSO or LY2109761

2021-03-07 | GSE111674 | GEO

RNA sequencing of Patient-Derived Xenografts

Project description:RNA sequencing of Patient-Derived Xenografts

| PRJNA1026533 | ENA

Patient-derived Human Breast Cancer Xenografts

Project description:Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that reflect patient tumor biology accurately. To overcome these limitations, we propagated a cohort of human breast tumors grown in the epithelium-free mammary fat pad of SCID/Beige and NOD/SCID/IL2γ-receptor null (NSG) mice, under a series of transplant conditions. Both models yielded stably transplantable xenografts at comparably high rates (~23% and ~19%, respectively). Of the conditions tested, xenograft take rate was highest in the presence of a low-dose estradiol pellet. Overall, 32 stably transplantable xenograft lines were established, representing unique 25 patients. Most tumors yielding xenografts were “triple-negative” (ER-PR-HER2+) (n=19). However, we established lines from three ER-PR-HER2+ tumors, one ER+PR-HER2-, one ER+PR+HER2- and one “triple-positive” (ER+PR+HER2+) tumor. Serially passaged xenografts show biological consistency with the tumor of origin, are phenotypic stability across multiple transplant generations at the histological, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses. Xenografts representing 12 patients, including two ER+ lines, showed metastasis to the mouse lung. These models thus serve as a renewable, quality-controlled tissue resource for preclinical studies investigating treatment response and metastasis. The study was designed to determine how stable patient-derived xenografts are across multiple transplant generations in mice, and to determine how closely xenografts established with pre-treatment samples cluster with xenografts established with post-treatment samples. Overall, pre-treatment and post-treatment samples derived from the same patient cluster together, and multiple transplant generations of xenografts derived from an individual patient cluster together.

2013-05-30 | E-GEOD-46106 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data